Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAB GTPase activating protein 1-like (RABGAP1L)
- Target
- RABGAP1L
- Molecular classification
- Enzyme, GTPase activating protein / small GTPase regulator, endosomal trafficking regulator
01
Overview
RAB GTPase activating protein 1-like (RABGAP1L) is a cytosolic enzyme that regulates endosomal trafficking by inactivating RAB22A via GTP hydrolysis[2][3]. It possesses a TBC domain crucial for its GTPase activating function, as well as N-terminal PTB and kinesin-like domains[2]. RABGAP1L plays a central role in cell migration, protein sorting, and immune response modulation, especially in the context of antiviral defense where it restricts influenza A virus entry by disrupting endosomal maturation and fusion[2]. Altered RABGAP1L expression and copy number variation have been linked to autoimmune disease (systemic lupus erythematosus) and neurodegenerative disorders (including Alzheimer’s disease), highlighting its role in cellular homeostasis, immunity, and neuronal function[1][2][3].
- Other names
- TBC1D18KIAA0471RBG10_HUMANRBG1L_HUMAN
02
Mechanism of action
Not directly targeted by known drugs. Its endogenous mechanism involves: - Inactivation of RAB22A (a small GTPase) - Promotion of endosomal trafficking, especially in immune and antiviral contexts
03
Biological functions
Intracellular protein transportRegulation of endosomal traffickingGTPase activator activityRegulation of protein localizationAntiviral response (limits replication of viruses such as influenza A in an interferon-dependent manner)Directional cell migration (promotes polarized trafficking in cell migration contexts)
04
Disease associations
Neurodegenerative diseases (e.g., Alzheimer’s disease)Autoimmune disease (e.g., systemic lupus erythematosus)Infection/Antiviral response (host restriction factor for influenza A and other viruses)Cholesteatoma, congenital
05
Safety considerations
Not established as a direct drug target, so safety profiles are undetermined.
06
Interacting drugs
None specifically identified in current databases or literature.
07
Biomarkers
None established for patient selection or monitoring; changes in RABGAP1L expression may have relevance in SLE and Alzheimer’s disease, but clinical biomarker use is not described.
Beyond the preview
Go deeper on RAB GTPase activating protein 1-like (RABGAP1L).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAB GTPase activating protein 1-like (RABGAP1L).